![[current-page:title] logo](/sites/default/files/styles/logo/public/default_images/_no-logo.png?itok=8OH0tuUw){kind=logo}
Address
Mediphase Venture Partners
2223 Washington Street
Suite 102 3 Newton Executive Park
Newton, MA 02462
United States
Phone
Email
Website
Recent investment activity
KANDO id: 30493
Corporate information
Registration country
Funding rounds
Investment activity status
Active investor
Selected investments
Displaying 1 - 13 of 13| Company | Profile | Country | Date | Funding | ||
|---|---|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Critical Therapeutics Inc | Discoverer, developer and commercialize novel therapies. | N/A | |||
|
|
DiscoveRx Corp | N/A | ||||
|
|
Health Market Science Inc | Provider of database including HCPs, HCOs, and affiliations. | N/A | |||
|
|
ImpactRX Inc | N/A | ||||
|
|
Optimer Pharmaceuticals Inc | Global biopharmaceutical company. | N/A | |||
|
|
PatientKeeper Inc | N/A | ||||
|
|
Relypsa Inc | Leads the discovery and development of new non-absorbed polymeric drugs | Series A | |||
|
|
Roxro Pharma Inc | Develops drugs for pain treatment | N/A | |||
|
|
Serenex Inc | Oncology-focused drug development company | Series B | |||
|
|
Tetraphase Pharmaceuticals Inc | A biopharmaceutical company utilizing a synthetic chemistry technology platform to treat drug-resistant bacterial infections. | Series C | |||
|
|
Tetraphase Pharmaceuticals Inc | A biopharmaceutical company utilizing a synthetic chemistry technology platform to treat drug-resistant bacterial infections. | Series A | |||
|
|
Tetraphase Pharmaceuticals Inc | A biopharmaceutical company utilizing a synthetic chemistry technology platform to treat drug-resistant bacterial infections. | Series B | |||
|
|
Concert Pharmaceuticals Inc | A biotechnology company creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. | Series C |
Team
| Employee | Position | |||
|---|---|---|---|---|
| Paul A Howard | [email protected] | |||
| David C Lubner | [email protected] | |||
| Lawrence G Miller | [email protected] |